193 related articles for article (PubMed ID: 28735823)
21. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
[TBL] [Abstract][Full Text] [Related]
22. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
23. Impact of Curcumin on Traumatic Brain Injury and Involved Molecular Signaling Pathways.
Farkhondeh T; Samarghandian S; Roshanravan B; Peivasteh-Roudsari L
Recent Pat Food Nutr Agric; 2020; 11(2):137-144. PubMed ID: 31288732
[TBL] [Abstract][Full Text] [Related]
24. Effects of the Use of Curcumin on Ulcerative Colitis and Crohn's Disease: A Systematic Review.
Goulart RA; Barbalho SM; Lima VM; Souza GA; Matias JN; Araújo AC; Rubira CJ; Buchaim RL; Buchaim DV; Carvalho ACA; Guiguer ÉL
J Med Food; 2021 Jul; 24(7):675-685. PubMed ID: 33155879
[TBL] [Abstract][Full Text] [Related]
25. Review of local injection of anti-TNF for perianal fistulising Crohn's disease.
Adegbola SO; Sahnan K; Tozer PJ; Phillips RK; Faiz OD; Warusavitarne J; Hart A
Int J Colorectal Dis; 2017 Nov; 32(11):1539-1544. PubMed ID: 28900730
[TBL] [Abstract][Full Text] [Related]
26. Curcumin attenuates allergic airway inflammation by regulation of CD4+CD25+ regulatory T cells (Tregs)/Th17 balance in ovalbumin-sensitized mice.
Ma C; Ma Z; Fu Q; Ma S
Fitoterapia; 2013 Jun; 87():57-64. PubMed ID: 23500387
[TBL] [Abstract][Full Text] [Related]
27. Levels of portal and systemic blood cytokines after colectomy in patients with carcinoma or Crohn's disease.
Riché F; Dosquet C; Panis Y; Valleur P; Laisné MJ; Briard C; Wautier JL
J Am Coll Surg; 1995 Jun; 180(6):718-24. PubMed ID: 7773486
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
29. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
30. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
[TBL] [Abstract][Full Text] [Related]
31. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.
Feagan BG; Lémann M; Befrits R; Connell W; D'Haens G; Ghosh S; Michetti P; Ochsenkühn T; Panaccione R; Schreiber S; Silverberg M; Sorrentino D; van der Woude CJ; Vermeire S; Rutgeerts P
Inflamm Bowel Dis; 2012 Jan; 18(1):152-60. PubMed ID: 22038857
[TBL] [Abstract][Full Text] [Related]
32. Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease.
Brown P; Clark T; Dowson G; Warren L; Hamlin J; Hull M; Subramanian V
J Crohns Colitis; 2016 Oct; 10(10):1144-50. PubMed ID: 26995185
[TBL] [Abstract][Full Text] [Related]
33. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
Smith LS; Nelson M; Dolder CR
Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
Shao LM; Chen MY; Cai JT
Aliment Pharmacol Ther; 2009 Mar; 29(6):605-14. PubMed ID: 19183161
[TBL] [Abstract][Full Text] [Related]
35. [Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease].
Holtmann M; Wanitschke R; Helisch A; Bartenstein P; Galle PR; Neurath M
Z Gastroenterol; 2003 Jan; 41(1):11-7. PubMed ID: 12541166
[TBL] [Abstract][Full Text] [Related]
36. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
37. The use of an anti-inflammatory supplement in patients with chronic kidney disease.
Moreillon JJ; Bowden RG; Deike E; Griggs J; Wilson R; Shelmadine B; Cooke M; Beaujean A
J Complement Integr Med; 2013 Jul; 10():. PubMed ID: 23828329
[TBL] [Abstract][Full Text] [Related]
38. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
Osamura A; Suzuki Y
Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
[TBL] [Abstract][Full Text] [Related]
39. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
[TBL] [Abstract][Full Text] [Related]
40. Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn's disease.
Detková Z; Kupcová V; Príkazská M; Turecký L; Weissová S; Jahnová E
Physiol Res; 2003; 52(1):95-100. PubMed ID: 12625813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
